Psyence Biomedical (PBM) Long-Term Investments (2023 - 2026)

Psyence Biomedical's Long-Term Investments history runs 3 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 982.0% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 982.0% increase from a year earlier, with the FY2026 full-year figure at $8.1 million, up 982.0% from the prior year.
• Long-Term Investments climbed to $8.1 million in Q1 2026 per PBM's latest filing, from $745000.0 in the prior quarter.
• Across five years, Long-Term Investments topped out at $12518.2 billion in Q3 2023 and bottomed at $745000.0 in Q1 2025.
• The 3-year median for Long-Term Investments is $8.1 million (2026), against an average of $4172.7 billion.
• Biggest YoY gain for Long-Term Investments was 982.0% in 2026; the steepest drop was 982.0% in 2026.
• Year by year, Long-Term Investments stood at $12518.2 billion in 2023, then slumped by 100.0% to $745000.0 in 2025, then soared by 982.0% to $8.1 million in 2026.
• Per Business Quant, the three latest PBM Long-Term Investments figures stand at $8.1 million (Q1 2026), $745000.0 (Q1 2025), and $12518.2 billion (Q3 2023).